Ludger Dinkelborg, PhD
Director of the Board, Life Molecular Imaging SA
Member of the Board, Life Molecular Imaging Inc
Managing Director, Life Molecular Imaging GmbH
Director of the Board, Life Molecular Imaging Ltd
Before joining Life Molecular Imaging, Dr. Dinkelborg served as Managing Director of Piramal Imaging GmbH, as Director of the Board of Piramal Imaging SA and was the Head of Diagnostic Imaging Research at Bayer HealthCare. He brings more than 20 years of R&D experience in the pharmaceutical industry.
He received his PhD in biology at Heinrich-Heine-University, Düsseldorf, Germany and stayed as guest researcher at the Max-Planck-Institute for Molecular Physiology in Dortmund. He became a fellow of the Konrad-Adenauer-Foundation, attended the Cranfield Schering University course for managers, and the Stanford Executive Program, at Stanford School of Business, Stanford, CA.
Andrew Stephens, MD, PhD
Chief Medical Officer
Dr. Stephens has more than 20 years of experience in the pharmaceutical industry, primarily in the areas of neurodegenerative diseases, oncology and diagnostic imaging. Previously, he was Chief Medical Officer at Piramal Imaging and the VP Head Experimental Medicine Oncology/Diagnostic Imaging for Bayer Pharma. He has held positions of increasing responsibility at NeXagen/NeXstar, Gilead, Schering AG, and OSI Pharmaceuticals.
He received his BA cum laude in chemistry from the University of Colorado, Boulder. He also received an MD with honors and a PhD in biochemistry, biophysics and genetics from the University of Colorado, Boulder. Dr. Stephens is Board certified in Internal Medicine and had a clinical practice before entering pharmaceutical development.
Susan De Santi, PhD
VP, Medical Affairs, North America and Asia Pacific
Dr. Susan De Santi is the VP of Medical Affairs for North America and Asia Pacific with six years of industry experience in diagnostic molecular imaging in both clinical development and Medical Affairs. Previously, she was the Global Medical Director, PET Neurology, Life Sciences, GE Healthcare and the Director, Global Clinical Development in Diagnostic Imaging at Bayer Healthcare Pharmaceuticals.
Susan was the 2015 Chairperson for the Private Partner Scientific Board of The Alzheimer’s Disease Neuroimaging Initiative (ADNI) and represents the interest of Piramal Imaging in other Alzheimer and Dementia Initiatives. She is a member of SNMMI and is on the Board of Directors of the Public Health Foundation Enterprises. Susan has co- authored more than 60 peer-reviewed articles, 10 book chapters and co-edited 1 book.
Prior to joining Life Molecular Imaging and Piramal, Susan was an Associate Professor in the Department of Psychiatry, at New York University Langone Medical Center. In addition she was the Administrative Director at the Center for Brain Health and retains an adjunct Associate Professorship at this institution. She received her PhD from The Graduate School and University Center of CUNY with an emphasis in Neurolinguistics. Susan’s research focused on early diagnostic markers of mild cognitive impairment and Alzheimer’s disease using brain imaging (MRI, FDG and amyloid PET), biological markers, and cognition.
Colleen Ruby, CNMT, RT(N)
Head of Commercial Operations, US and RoW
Director of the Board, Life Molecular Imaging Inc
Ms. Ruby is Life Molecular Imaging’s Head of Commercial Operations for US and RoW. She joined the organization in 2014 as Piramal Imaging’s Head of National Sales in the US to identify the market, establish the company’s brand, and to build a salesforce for the launch of Neuraceq (florbetaben F-18). Ms. Ruby is committed to executing Life Molecular’s innovative initiatives to bring new direction to the PET market and to the advancement of molecular imaging.
Ms. Ruby is a Certified and Registered Nuclear Medicine Technologist with more than thirty years of healthcare experience. She holds a degree in Science in Nuclear Medicine Technology and continuously updates her skill-set via continuing education courses in health and business applications. Prior to joining the company, Ms. Ruby served as IBA Molecular’s Vice President of Sales and Marketing where she cultivated a professional organization of high-level Sales and Marketing specialists in the Nuclear and Molecular disciplines of the healthcare industry. Ms. Ruby was also previously employed by The University of Pittsburgh Medical Center. She is an active member of the Society of Nuclear Medicine Molecular Imaging and participates on behalf of company in the Medical Imaging and Technology Alliance.
VP of Commercial Operations, Europe
Nico Beukman is the VP of Commercial Operations Europe at Life Molecular Imaging Ltd, and has served as the Director and Secretary to the Board of Piramal Imaging Limited for the past two years.
Mr. Beukman has more than 20 years of experience in the medical industry with a proven track record for managing strategic growth and execution of sales, marketing and commercial activities. Throughout his career, he has implemented creative and effective solutions for driving revenue growth and improving profitability while managing multinational teams.
Prior to Life Molecular Imaging and Piramal Imaging, Mr. Beukman spent twelve years at Covidien now Mallinckrodt serving the company in various roles. Most recently, Mr. Beukman was the Vice President of Marketing for Pharmaceuticals and Imaging Solutions at Covidien. He was responsible for all marketing activities for sales in Europe, the Middle East and Africa for contrast media, devices, consumables and nuclear medicine product portfolios. Mr. Beukman earned his diploma in Clinical Engineering at Tswane University of Technology in South Africa.